Caio Max Rocha Lima to Neoplasm Metastasis
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Neoplasm Metastasis.
Connection Strength
0.691
-
Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med. 2010 Nov-Dec; 77(6):606-19.
Score: 0.343
-
Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol. 2014 Apr; 73(4):839-45.
Score: 0.108
-
Lopes G, Quesada J, Ahn E, Flores A, Ribeiro A, Rocha-Lima CM. Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual. Clin Colorectal Cancer. 2007 Sep; 6(9):641-5.
Score: 0.069
-
de Lima Lopes G, Rocha Lima CM. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib. Pharmacotherapy. 2007 May; 27(5):775-7.
Score: 0.067
-
Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, Tolba K, Farfan N, Hamilton-Nelson K, Silva O, Roman E. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 2006 Sep; 53(3):347-53.
Score: 0.064
-
Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842.
Score: 0.024
-
Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM, Benson AB. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007 Feb; 30(1):26-31.
Score: 0.017